ADX 71149

Drug Profile

ADX 71149

Alternative Names: ADX-71149; JNJ-40411813; JNJ-mGluR2-PAM

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics; Janssen Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Anxiolytics; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Major depressive disorder; Psychiatric disorders; Schizophrenia

Most Recent Events

  • 27 Feb 2017 Addex Therapeutics and Janssen Pharmaceuticals plan a phase IIa proof of concept trial for Epilepsy
  • 06 Dec 2016 Discontinued - Phase-I for Psychiatric disorders (In volunteers) in USA (PO) (Addex Therapeutics pipeline, December 2016)
  • 06 Dec 2016 Discontinued - Phase-II for Schizophrenia (Adjunctive treatment) in Bulgaria, Spain, Romania, Germany, Belgium, Austria (PO) (Addex Therapeutics pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top